Showing results (411-420 of 470) with videos related to
Sort By:
Pageof 47
NEJM Evidence|July 23, 2024
Clinical and Genomic Risk for Late Breast Cancer Recurrence and SurvivalJoseph A Sparano, Michael Crager, Robert J Gray, et al.NPJ Breast Cancer|October 24, 2025
CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trialAndrea E Wahner Hendrickson, Karen S Flatten, Taylor M Weiskittel, et al.JNCI Cancer Spectrum|May 23, 2022
Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical TrialsNadine J McCleary, William S Harmsen, Ellana Haakenstad, et al.JAMA Oncology|March 9, 2023
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical TrialTufia C Haddad, Vera J Suman, Antonino B D'Assoro, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2018
Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast CancerDiana C West, Masha Kocherginsky, Eva Y Tonsing-Carter, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2023
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast CancerJamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 6, 2014
TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancerRoisin M Connolly, Jeffrey P Leal, Matthew P Goetz, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 27, 2020
Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor αJames N Ingle, Junmei Cairns, Vera J Suman, et al.Journal for Immunotherapy of Cancer|June 3, 2026
Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancerYi Liu, Jodi M Carter, Yaohua Ma, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2022
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT TrialsOlivia Pagani, Barbara A Walley, Gini F Fleming, et al.Pageof 47